Cited by 134Protease and Inhibitor MechanismsAlzheimer's disease research and treatmentsNeuroinflammation and Neurodegeneration Mechanisms

Cystatin C in aging and in Alzheimer’s disease

Open access
Mathews, Paul M., Levy, Efrat·2016·Ageing Research Reviews

Abstract

Under normal conditions, the function of catalytically active proteases is regulated, in part, by their endogenous inhibitors, and any change in the synthesis and/or function of a protease or its endogenous inhibitors may result in inappropriate protease activity. Altered proteolysis as a result of an imbalance between active proteases and their endogenous inhibitors can occur during normal aging, and such changes have also been associated with multiple neuronal diseases, including Amyotrophic Lateral Sclerosis (ALS), rare heritable neurodegenerative disorders, ischemia, some forms of epilepsy, and Alzheimer's disease (AD). One of the most extensively studied endogenous inhibitor is the cysteine-protease inhibitor cystatin C (CysC). Changes in the expression and secretion of CysC in the brain have been described in various neurological disorders and in animal models of neurodegeneration, underscoring a role for CysC in these conditions. In the brain, multiple in vitro and in vivo findings have demonstrated that CysC plays protective roles via pathways that depend upon the inhibition of endosomal-lysosomal pathway cysteine proteases, such as cathepsin B (Cat B), via the induction of cellular autophagy, via the induction of cell proliferation, or via the inhibition of amyloid-β (Aβ) aggregation. We review the data demonstrating the protective roles of CysC under conditions of neuronal challenge and the protective pathways induced by CysC under various conditions. Beyond highlighting the essential role that balanced proteolytic activity plays in supporting normal brain aging, these findings suggest that CysC is a therapeutic candidate that can potentially prevent brain damage and neurodegeneration.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.arr.2016.06.003

Cites

256 of 256 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • SPARC is down-regulated in MG (IBA1-positive cells) with aging.

    “our scRNA-seq and others 24,27 ), and the aging-related down-regulation of SPARC in MG (IBA1-positive cells; indicated by arrows).”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 257 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

  1. Price DL Martin LJ Sisodia SS Walker LC Voytko ML Wagster MV Cork LC Koliatsos VE Terry RD Katzman R Blick KL The aged nonhuman primate. A model for the behavioral and brain abnormalities occurring in aged humans Alzheimer's disease 1994 New York Raven Press 231 245

Cited by

Sorted by citations

Authors
Mathews, P. M., & Levy, E.
Affiliations
Nathan Kline Institute for Psychiatric Research (US)
Corresponding author
Levy, Efrat
Venue
Ageing Research Reviews
Publisher
Elsevier BV
Published
2016-12
Volume
32
Pages
38-50
ISSN
1568-1637 (ISSN-L)
OpenAlex
W2432488913
Cited by
133
References
257
Citations by year
2026: 10 · 2025: 17 · 2024: 10 · 2023: 22 · 2022: 10 · 2021: 7 · 2020: 19 · 2019: 19 · 2018: 11 · 2017: 7 · 2016: 1
FWCI
1.15
Type
journal article
Language
en
Open access
Locations
  • Ageing Research Reviews (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Institutes of Health (AG017617, AG037693)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Protease and Inhibitor Mechanisms
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
cystatin C, Alzheimer's disease, brain aging, cysteine protease inhibitors, cathepsin B, endolysosomal pathway, autophagy, amyloid-beta aggregation, neuroprotection, neurodegeneration
MeSH terms
Aging, Alzheimer Disease, Animals, Autophagy, Brain, Humans, Nerve Degeneration, Amyloid beta-Peptides, Cystatin C, Protective Factors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review